Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy.
Forty-three patients with evaluable metastatic breast cancer refractory to hormonal agents and extensive combination chemotherapy including doxorubicin were treated with mitomycin, 20 mg/m2 intravenously every 6 weeks. There were five partial responses (12%) and three minor responses (7%), with a mean time to progression of 5 months and 3.5 months, respectively. Thrombocytopenia was the major dose-limiting toxicity, and myelosuppression was cumulative. Cardiac dysfunction was observed in 12% of patients. Mitomycin had some antitumor activity in this group of metastatic breast cancer patients refractory to extensive combination chemotherapy including doxorubicin.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004351:Drug Resistance; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced
D006728:Hormones; D008937:Mitomycins